Dignitana’s CEO Catarina Mård Löwenadler resigns – Fredrik Jonsson appointed as new CEO
Dignitana AB announces today that Catarina Mård Löwenadler, CEO of Dignitana, after consulting with the Board of Directors, will resign as CEO on 2 May 2024, and that Fredrik Jonsson will assume the position as new CEO on the same day. To ensure a smooth transition, Catarina Mård Löwenadler will remain at Dignitana for a period after Fredrik Jonsson has assumed the position of CEO of the Company.
“On behalf of the Board, I would like to thank Catarina for the good work she has done at Dignitana. Among other things, she has been a valuable contributor to the development of Dignitana’s strategic plan and a driving force in creating a strong governance structure, which ultimately has created a solid foundation for continued growth and profitability. We wish her all the best in her future career,” comments Klas Arildsson, Chairman of the Board.
”I appreciate the time that I have spent at Dignitana and wish the company and my successor all the best as Dignitana continues to grow,” says Catarina Mård Löwenadler, CEO of Dignitana.
Fredrik Jonsson, who assumes the role of CEO on 2 May 2024, is an accomplished leader with a focus on entrepreneurship, sales, marketing, and strategy. With extensive experience in both large and small MedTech organizations, Fredrik brings valuable expertise to the Company. He comes most recently from the role as CEO of Spotlight-listed Alteco Medical AB, was previously CEO of Distributed Medical AB, and has held senior positions in companies operating in the fields of endoscopy and dentistry.
”I take on the role as CEO of Dignitana with humility, as it is an assignment with great responsibility and the opportunity to positively impact the lives of cancer patients at a critical time in their treatment. I look forward to helping the team deliver on Dignitana’s strategic priorities in my new role,” says Fredrik Jonsson.
”We are pleased that Fredrik has chosen to join Dignitana as CEO to lead the company in our continued development toward profitability,” adds Klas Arildsson, Chairman of the Board.
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-04-2024 18:03 CET.
For More Information Contact
Melissa Bourestom, Chief Communications Officer, melissa.bourestom@dignitana.com +1 469-518-5031
About Dignitana
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.
Tags: